Latest:
Prognostic Significance of Post-Treatment PET/CT Following Salvage Re-irradiation of Head and Neck Cancers
Researchers explored the prognostic significance of PET/CT following re-irradiation in patients with head and neck cancer.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Jing Zeng, MD
Latest:
Radiotherapy in the Modern Era in the Management of Langerhans Cell Histiocytosis
Intensity-modulated radiotherapy reduces the mean radiation dose delivered to critical normal structures and should be considered in Langerhans cell histiocytosis treatment when radiotherapy is indicated, particularly given the expected, long-term survival of these patients.
Jing-Zhou Hou, MD, PhD
Latest:
Dr. Hou on Polatuzumab Vedotin in DLBCL
Jing-Zhou Hou, MD, PhD, co-chair of the Hematological Malignancies program, and medical oncologist, hematologist, and clinical instructor at University of Pittsburgh Medical Center Hillman Cancer Center, discusses the use of polatuzumab vedotin (Polivy) in diffuse large B-cell lymphoma (DLBCL).
Jivesh Sharma, MD
Latest:
Opportunities and Challenges: A Time to Reflect at the End of a Busy Year
It is the final month of what has been economically a very tough year. Oncology centers and practices continue to face declining reimbursements on all service lines, and most have had either flat or lower revenues.
Joan Lunden
Latest:
Joan Lunden and Dr Patrick Borgen Discuss Imaging and Genetic Testing in Breast Cancer
Joan Lunden talks about imaging technology and genetic testing for the early detection of breast cancer with Roy Firestone and Patrick I. Borgen, MD, in advance of her keynote address at the 32nd Miami Breast Cancer Conference.
Joanne Blum, MD, PhD
Latest:
Dr. Blum on Takeaways from ABC Trials for Breast Cancer
Joanne Blum, MD, PhD, FACP, physician, Texas Oncology, discusses the key takeaways from the phase III ABC (anthracyclines in early breast cancer) trials, which compared docetaxel plus cyclophosphamide versus anthracycline/taxane-based chemotherapy regimens in patients with high-risk, HER2-negative breast cancer.
Joanne E. Filicko-O’Hara, MD
Latest:
Day in the Life of an Oncology/Hematology Fellowship Program Director
Trainees have sat in this hot seat at the front of the room for decades. It's not really warm, of course. This is where the fellow sits who is asked to review the findings, come up with a differential diagnosis, and devise a plan for the case in question.
Jody Sheehan Garey, PharmD
Latest:
Compatibility Check: Can Precision Medicine and Pathways Co-Exist?
One of the most widely talked about trends in healthcare is precision
medicine, which uses detailed genetic information about a patient’s cancer to
more precisely treat the disease, effectively targeting the tumor. This heightened
awareness raises an important question: are precision medicine and
pathways compatible?